Serum and urinary biomarkers determination and their significance in diagnosis of kidney diseases

Journal of Medical Biochemistry

Volumn 29, Issue 4, 2010, Pages 288-297

  Ležaić, Višnja ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

acute kidney injury; biomarkers in the blood or urine; chronic kidney disease

Indexed keywords

BIOLOGICAL MARKER; CREATININE; INTERLEUKIN 6; PROCALCITONIN; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA1;

BLOOD LEVEL; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MORBIDITY; MORTALITY; REVIEW; URINE LEVEL;

EID: 77958086780     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-010-0046-3     Document Type: Review

References (87)

1. Locatelli F, Vecchio LD, Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol Dial Transplant 2002; 17: 2-7.
2. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601-8.
3. Srisawat N, Hoste EE, Kellum JA. Modern classification of acute kidney injury. Blood Purif 2010; 29: 300-7.
4. NKF. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
5. Waikar SS, Bonventre J V. Can we rely on blood urea nitrogen as a biomarker to determine when to initiate dialysis? Clin J Am Soc Nephrol 2006; 1: 903-4.
6. Schwartz GJ, Kwong T, Erway B, Warady B, Sokoll L, Hellerstein S, et al. Validation of creatinine assays utilizing HPLC and IDMS traceable standards in sera of children. Pediatr Nephrol 2009; 24: 113-19.
7. Rule AD. Understanding estimated glomerular filtration rate: implications for identifying chronic kidney disease. Curr Opin Nephrol Hypertens 2007; 16: 242-9.
8. Curhan G. Cystatin C: a marker of renal function or something more? Clin Chem 2005; 51: 293-4.
9. Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 61: 1453-61.
10. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, Philipp T, Kribben A. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-22.
11. Herget-Rosenthal S, Poppen D, Husing J, Marggraf G, Pietruck F, Jakob HG, Philipp T, Kribben A. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 2004; 50: 552-8.
12. Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009; 18: 526-30.
13. Urushihara M, Kondo S, Kagami S, Kobori H. Urinary Angiotensinogen Accurately Reflects Intrarenal Renin-Angiotensin System Activity. Am J Nephrol 2010; 31: 318-25.
14. Deekajorndech T. A biomarker for detecting early tu bulo interstitial disease and ischemia in glomerulo nephropathy. Ren Fail 2007; 29: 1013-17.
15. DeRubertis FR, Craven PA, Melhem M F. Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol. Metabolism 2007; 56: 1256-64.
16. Oberg B P, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-16.
17. Dincer Y, Sekercioglu N, Pekpak M, Gunes KN, Akcay T. Assessment of DNA oxidation and antioxidant activity in hypertensive patients with chronic kidney disease. Ren Fail 2008; 30: 1006-11.
18. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis K P, Tselepis A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006; 48: 752-60.
19. Nakamura N, Kumasaka R, Osawa H, Yamabe H, Shirato K, Fujita T, et al. Effects of eicosapentaenoic acids on oxidative stress and plasma fatty acid composition in patients with lupus nephritis. In Vivo 2005; 19: 879-82.
20. Calabrese V, Mancuso C, Sapienza M, Puleo E, Calafato S, Cornelius C, et al. Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones 2007; 12: 299-306.
21. Radabaugh MR, Nemirovskiy OV, Misko T P, Aggarwal P, Mathews WR. Immunoaffinity liquid chromatography-tandem mass spectrometry detection of nitrotyrosine in biological fluids: development of a clinically translatable biomarker. Anal Biochem 2008; 380: 68-76.
22. Furuya R, Kumagai H, Odamaki M, Takahashi M, Miyaki A, Hishida A. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients. Nephron Clin Pract 2009; 112: c255-61.
23. Olak E, Majkić-Singh N. The effect of hyperglycemia and oxidative stress on the development and progress of vascular complications in type 2 diabetes. Journal of Medical Biochemistry 2009; 28: 63-71.
24. Polkinghorne KR. Detection and measurement of urinary protein. Curr Opin Nephrol Hypertens 2006; 15: 625-30.
25. Comper WD, Osicka TM, Clark M, MacIsaac RJ, Jerums G. Earlier detection of microalbuminuria in diabetic patients using a new urinary albumin assay. Kidney Int 2004; 65: 1850-5.
26. Magliano DJ, Polkinghorne KR, Barr EL, Su Q, Chadban SJ, Zimmet PZ, et al. HPLC-detected albuminuria predicts mortality. J Am Soc Nephrol 2007; 18: 3171-6.
27. Wang G, Lai FM, Lai KB, Chow KM, Li KT, Szeto CC. Messenger RNA expression of podocyte-associated molecules in the urinary sediment of patients with diabetic nephropathy. Nephron Clin Pract 2007; 106: c169-79.
28. Wang G, Lai FM, Tam LS, Li KM, Lai KB, Chow KM, et al. Messenger RNA expression of podocyte-associated molecules in urinary sediment of patients with lupus nephritis. J Rheumatol 2007; 34: 2358-64.
29. Kanno K, Kawachi H, Uchida Y, Hara M, Shimizu F, Uchiyama M. Urinary sediment podocalyxin in children with glomerular diseases. Nephron Clin Pract 2003; 95: c91-9.
30. Bazzi C, Petrini C, Rizza V, Arrigo G, Napodano P, Paparella M, et al. Urinary N-acetyl-betaglucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002; 17: 1890-6.
31. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73: 863-9.
32. Van Timmeren MM, Van den Heuvel MC, Bailly V, Bakker SJ, Van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007; 212: 209-17.
33. Vaidya VS, Ford GM, Waikar SS, Wang Y, Clement MB, Ramirez V, et al. A rapid urine test for early detection of kidney injury. Kidney Int 2009; 76: 108-14.
34. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre J V. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002; 62: 237-44.
35. Simić-Ogrizović S. The importance of KIM-1 deter mination in tissue and urine of patients with different kidney diseases. Journal of Medical Biochemistry 2010; 29: 304-9.
36. Liangos O, Han WK, Wald R, Perianayagam MC, Balakrishnan VS, MacKinnon RW, Warner K, Symes J F, Li L, Kouznetsov A, Pereira BJG, Bonventre J V, Jaber BL. Urinary Kidney Injury Molecule-1 (KIM-1) and N-Acetyl(b)-D-Glucosaminidase (NAG) Levels in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass (CPB). J Am Soc Nephrol 2005; 16: 318A.
37. Liangos O, Han WK, Wald R, Perianayagam MC, Balakrishnan VS, MacKinnon RW, Li L, Pereira BJG, Bonventre J V, Jaber BL. Urinary Kidney Injury Molecule-1 Levels Are Associated with Renal Replacement Therapy (RRT) and Death in Acute Renal Failure (ARF). J Am Soc Nephrol 2005; 16: 318A.
38. Portilla D, Dent C, Sugaya T, Nagothu KK, Kundi I, Moore P, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008; 73: 465-72.
39. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med 2005; 145: 125-33.
40. Negishi K, Noiri E, Sugaya T, et al. A role of liver fatty acid binding protein in cisplatin-induced acute renal failure. Kidney Int 2007; 72: 348-58.
41. Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 2007; 18: 2894-902.
42. Kamijo A, Sugaya T, Hikawa A, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 2006; 284: 175-82.
43. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003; 14: 2534-43.
44. Mori K, Nakao K. Neutrophil gelatinase-associated lipo calin as the real-time indicator of active kidney damage. Kidney Int 2007; 71: 967-70.
45. Pickering JW, Endre ZH. Secondary prevention of acute kidney injury. Curr Opin Crit Care 2009; 15: 488-97.
46. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 337-44.
47. Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S. NGAL (neutrophil gelatinase-associated lipocalin) and L-FABP after percutaneous coronary interventions due to unstable angina in patients with normal serum creatinine. Advances in Medical Sciences 2009; 54: 221-4.
48. Schmidt-Ott KM, Mori K, Li J Y, Kalandadze A, Cohen DJ, Devarajan P, et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007; 18: 407-13.
49. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006; 105: 485-91.
50. Bazzi C, Petrini C, Rizza V, Napodano P, Paparella M, Arrigo G, et al. Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: a pilot study. Am J Kidney Dis 2003; 41: 328-35.
51. Tan Y, Zhang JJ, Liu G, Zhang H, Zhao MH. The level of urinary secretory immunoglobulin A (sIgA) of patients with IgA nephropathy is elevated and associated with pathological phenotypes. Clin Exp Immunol 2009; 156: 111-16.
52. Bakoush O, Segelmark M, Torffvit O, Ohlsson S, Tencer J. Urine IgM excretion predicts outcome in ANCA-associated renal vasculitis. Nephrol Dial Transplant 2006; 21: 1263-9.
53. Bakoush O, Torffvit O, Rippe B, Tencer J. Renal function in proteinuric glomerular diseases correlates to the changes in urine IgM excretion but not to the changes in the degree of albuminuria. Clin Nephrol 2003; 59: 345-52.
54. Branten AJ, Kock-Jansen M, Klasen IS, Wetzels J F. Urinary excretion of complement C3d in patients with renal diseases. Eur J Clin Invest 2003; 33: 449-56.
55. Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi S P, Sereika SM, et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996; 39: 1178-88.
56. Zhang JJ, Jiang L, Liu G, Wang SX, Zou WZ, Zhang H, et al. Levels of urinary complement factor H in patients with IgA nephropathy are closely associated with disease activity. Scand J Immunol 2009; 69: 457-64.
57. Endo M, Fuke Y, Tamano M, Hidaka M, Ohsawa I, Fujita T, et al. Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy. Nephron Clin Pract 2004; 97: c147-53.
58. Chow F Y, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin treated mice. Kidney Int 2006; 69: 73-80.
59. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu C Y, Nagaraja HN. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005; 16: 467-73.
60. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000; 58: 1492-9.
61. Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky E T, Roshan B, et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009; 4: 62-70.
62. Hu H, Aizenstein BD, Puchalski A, Burmania JA, Hamawy MM, Knechtle SJ. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am J Transplant 2004; 4: 432-7.
63. Matz M, Beyer J, Wunsch D, Mashreghi M F, Seiler M, Pratschke J, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short-and long-term graft function. Kidney Int 2006; 69: 1683-90.
64. Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007; 179: 7166-75.
65. Schramme A, Abdel-Bakky MS, Gutwein P, Obermuller N, Baer PC, Hauser IA, et al. Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int 2008; 74: 328-38.
66. Brown FG, Nikolic-Paterson DJ, Hill PA, Isbel NM, Dowling J, Metz CM, et al. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J Am Soc Nephrol 2002; 13 Suppl 1: S7-13.
67. Brown FG, Nikolić-Paterson DJ, Chadban SJ, Dowling J, Jose M, Metz CN, et al. Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection. Transplantation 2001; 71: 1777-83.
68. Tesar V, Masek Z, Rychlik I, Merta M, Bartunkova J, Stejskalova A, et al. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 1998; 13: 1662-7.
69. Lederer SR, Friedrich N, Regenbogen C, Getto R, Toepfer M, Sitter T. Non-invasive monitoring of renal transplant recipients: urinary excretion of soluble adhesion molecules and of the complement split product C4d. Nephron Clin Pract 2003; 94: c19-26.
70. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney trans plantation. Am J Transplant. 2006; 6: 1639-45.
71. Kilis-Pstrusinska K, Medynska A, Zwolinska D, Wawro A. Interleukin-18 in urine and serum of children with idiopathic nephrotic syndrome. Kidney Blood Press Res 2008; 31: 122-6.
72. Iglesias J, Marik PE, Levine JS. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis 2003; 41: 62-75.
73. Ting Y T, Coates P T, Marti H P, Dunn AC, Parker RM, Pickering J W, et al. Urinary soluble HLADR is a potential biomarker for acute renal transplant rejection. Trans plantation 2010; 89: 1071-8.
74. Tsakas S, Goumenos DS. Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol 2006; 26: 186-93.
75. Cheng O, Thuillier R, Sampson E, Schultz G, Ruiz P, Zhang X, et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant 2006; 6: 2292-306.
76. Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, et al. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 2003; 26: 2632-6.
77. Cha DR, Kim IS, Kang YS, Han S Y, Han KH, Shin C, et al. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus. Diabet Med 2005; 22: 14-20.
78. Ükanović Lj, Lèai V, Miljkovi, Momilovi M, Bukvi D, Mari I, et al. Transforming growth factor-b1 in Balkan endemic nephropathy. Nephron Clin Pract 2009; 111 (2): c127-32
79. Io H, Hamada C, Fukui M, Horikoshi S, Tomino Y. Relationship between levels of urinary type IV collagen and renal injuries in patients with IgA nephropathy. J Clin Lab Anal 2004; 18: 14-8.
80. Cohen M P, Lautenslager G T, Shearman CW. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice. Metabolism 2001; 50: 1435-40.
81. Zhou H, Pisitkun T, Aponte A, Yuen PS, Hoffert JD, Yasuda H, et al. Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int 2006; 70: 1847-57.
82. Schaub S, Wilkins JA, Antonovici M, Krokhin O, Weiler T, Rush D, et al. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant 2005; 5: 729-38.
83. Dihazi H, Muller GA, Lindner S, Meyer M, Asif AR, Oellerich M, et al. Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007; 53: 1636-45.
84. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005; 67: 2313-20.
85. Mosley K, Ta m FW, Edwards RJ, Crozier J, Pusey CD, Lightstone L. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 2006; 45: 1497-504.
86. Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007; 30: 638-43.
87. Rossing K, Mischak H, Dakna M, Zurbig P, Novak J, Julian BA, et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008; 19: 1283-90.